Targeting sphingosine 1 phosphate receptor type 1 receptors in acute kidney injury

Drug Discovery Today: Disease Mechanisms

Volumn 4, Issue 1, 2007, Pages 55-59

  Okusa, Mark D ^a   Lynch, Kevin R ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 PHENYL 5 TRIFLUOROMETHYL 2 THIENYL) 3 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 OXADIAZOLE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; FINGOLIMOD; RECEPTOR BLOCKING AGENT; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE ANTAGONIST; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE TYPE 1 RECEPTOR AGONIST; VPC 44116;

ACUTE DISEASE; CLINICAL TRIAL; DRUG APPROVAL; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOMODULATION; KIDNEY INJURY; KIDNEY ISCHEMIA; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; REPERFUSION INJURY; REVIEW;

EID: 47049091138     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2007.07.001     Document Type: Review

References (65)

1. Uchino S., et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294 (2005) 813-818
2. Bellomo R., et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit. Care 8 (2004) R204-R212
3. Liano F., and Pascual J. Outcomes in acute renal failure. Semin Nephrol. 18 (1998) 541-550
4. Chertow G.M., et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J. Am. Soc. Nephrol. 16 (2005) 3365-3370
5. Jo S.K., et al. Pharmacologic Treatment of Acute Kidney Injury. Why Drugs Haven't: Why Drugs Haven't Worked and What is on the Horizon. Clin. J. Am. Soc. Nephrol. 2 (2007) 256-365
6. Mason J., et al. Role of the medullary perfusion defect in the pathogenesis of ischemic renal failure. Kidney Int. 26 (1984) 283-293
7. Lieberthal W., et al. Renal ischemia and reperfusion impaired endothelium-dependent vascular relaxation. Am. J. Physiol. 256 (1989) F894-F900
8. Brodsky S.V., et al. Endothelial dysfunction in ischemic acute renal failure: rescue by transplanted endothelial cells. Am. J. Physiol. Renal Physiol. 282 (2002) F1140-F1149
9. Molitoris B.A., and Sutton T.A. Endothelial injury and dysfunction: role in the extension phase of acute renal failure. Kidney Int. 66 (2004) 496-499
10. Chan L., et al. Effect of endothelin-receptor antagonist on ischemic acute renal failure. Am. J. Physiol. 266 (1994) F135-F138
11. Goligorsky M.S. Whispers and shouts in the pathogenesis of acute renal ischaemia. Nephrol. Dial Transplant 20 (2005) 261-266
12. Hellberg P.O.A., et al. Peritubular capillary permeability and intravascular RBC aggregation after ischemia: effects of neutrophils. Am. J. Physiol. 258 (1990) F1018-F1025
13. Li L., and Okusa M.D. Blocking the Immune respone in ischemic acute kidney injury: the role of adenosine 2A agonists. Nat. Clin. Pract. Nephrol. 2 (2006) 432-444
14. Devarajan P. Update on mechanisms of ischemic acute kidney injury. J. Am. Soc. Nephrol. 17 (2006) 1503-1520
15. Bonventre J.V., and Weinberg J.M. Recent advances in the pathophysiology of ischemic acute renal failure. J. Am. Soc. Nephrol. 14 (2003) 2199-2210
16. Day Y.-J., et al. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J. Clin. Invest. 112 (2003) 883-891
17. Okusa M.D. The inflammatory cascade in acute ischemic renal failure. Nephron 90 (2002) 133-138
18. Friedewald J.J., and Rabb H. Inflammatory cells in ischemic acute renal failure. Kidney Int. 66 (2004) 486-491
19. Koo D.D., et al. Ischemia/reperfusion injury in human kidney transplantation: an immunohistochemical analysis of changes after reperfusion. Am. J. Pathol. 153 (1998) 557-566
20. Day Y.J., et al. Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: role of macrophages. Am. J. Physiol. Renal Physiol. 288 (2005) F722-F731
21. Jo S.K., et al. Macrophages contribute to the initiation of ischaemic acute renal failure in rats. Nephrol. Dial Transplant (2006)
22. Burne M.J., et al. Identification of the CD4+ T cell as a major pathogenic factor in ischemic acute renal failure. J. Clin. Invest. 108 (2001) 1283-1290
23. Wilson H.M., et al. Macrophages and the kidney. Curr. Opin. Nephrol. Hypertens 13 (2004) 285-290
24. Geissmann F., et al. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19 (2003) 71-82
25. Fogg D.K., et al. A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. Science 311 (2006) 83-87
26. Gordon S., and Taylor P.R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5 (2005) 953-964
27. Sunderkotter C., et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J. Immunol. 172 (2004) 4410-4417
28. Soos T.J., et al. CX3CR1+ interstitial dendritic cells form a contiguous network throughout the entire kidney. Kidney Int. 70 (2006) 591-596
29. Dong X., et al. Antigen presentation by dendritic cells in renal lymph nodes is linked to systemic and local injury to the kidney. Kidney Int. 68 (2005) 1096-1108
30. Steinman R.M., and Inaba K. Myeloid dendritic cells. J. Leukoc Biol. 66 (1999) 205-208
31. Chen Z., et al. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int. J. Cancer 93 (2001) 539-548
32. Robinson S.P., et al. Developmental aspects of dendritic cells in vitro and in vivo. Leuk Lymphoma 29 (1998) 477-490
33. Stosel H., et al. Maturation and migration of murine dendritic cells in situ. Observations in a skin organ culture model. Adv. Exp. Med. Biol. 417 (1997) 311-315
34. Munz C., et al. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J. Exp. Med. 202 (2005) 203-207
35. Day Y.-J., et al. Renal ischemia-reperfusion and adenosine 2A receptor-mediated tissue protection: The role of CD4+ T cells and inteferon gamma. J. Immunol. 176 (2006) 3108-3114
36. Ysebaert D.K., et al. T cells as mediators in renal ischemia/reperfusion injury. Kidney Int. 66 (2004) 491-496
37. Burne-Taney M.J., et al. Transfer of lymphocytes from mice with renal ischemia can induce albuminuria in naive mice: a possible mechanism linking early injury and progressive renal disease?. Am. J. Physiol. Renal Physiol. 291 (2006) F981-F986
38. Burne-Taney M.J., et al. Persistent renal and extrarenal immune changes after severe ischemic injury. Kidney Int. 67 (2005) 1002-1009
39. Li L., et al. NKT cell activation mediates neutrophil IFN-gamma production and renal ischemia-reperfusion injury. J. Immunol. 178 (2007) 5899-5911
40. Seino K., et al. Natural killer T cell-mediated antitumor immune responses and their clinical applications. Cancer Sci. 97 (2006) 807-812
41. Yasunami Y., et al. Valpha14 NK T cell-triggered IFN-gamma production by Gr-1+CD11b+ cells mediates early graft loss of syngeneic transplanted islets. J. Exp. Med. 202 (2005) 913-918
42. Spiegel S., and Milstien S. Functions of a new family of sphingosine-1-phosphate receptors. Biochim. Biophys Acta 1484 (2000) 107-116
43. Shida D., et al. Sphingosine 1-phosphate transactivates c-Met as well as epidermal growth factor receptor (EGFR) in human gastric cancer cells. FEBS Lett. 577 (2004) 333-338
44. Ancellin N., and Hla T. Differential pharmacological properties and signal transduction of the sphingosine 1-phosphate receptors EDG-1, EDG-3, and EDG-5. J. Biol. Chem. 274 (1999) 18997-19002
45. Spiegel S. Sphingosine 1-phosphate: a prototype of a new class of second messengers. J. Leukoc. Biol. 65 (1999) 341-344
46. Spiegel S., et al. Sphingosine 1-phosphate signaling: providing cells with a sense of direction. Trends Cell Biol. 12 (2002) 236-242
47. Spiegel S., and Milstien S. Sphingosine 1-phosphate, a key cell signaling molecule. J. Biol. Chem. 277 (2002) 25851-25854
48. Olivera A., et al. Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J. Cell Biol. 147 (1999) 545-558
49. Iwata M., et al. Sphingosine: a mediator of acute renal tubular injury and subsequent cytoresistance. Proc. Natl. Acad. Sci. U S A 92 (1995) 8970-8974
50. Brinkmann V., and Lynch K.R. FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr. Opin. Immunol. 14 (2002) 569-575
51. Nikolova Z., et al. The peripheral lymphocyte count predicts graft survival in DA to Lewis heterotopic heart transplantation treated with FTY720 and SDZ RAD. Transpl. Immunol. 8 (2000) 115-124
52. Paugh S.W., et al. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett. 554 (2003) 189-193
53. Xie J.H., et al. Sphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T cells. J. Immunol. 170 (2003) 3662-3670
54. Honig S.M., et al. FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes. J. Clin. Invest 111 (2003) 627-637
55. Sonoda Y., et al. FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells. Biochem. Biophys Res. Commun. 281 (2001) 282-288
56. Mandala S., et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296 (2002) 346-349
57. Brinkmann V. FTY720: mechanism of action and potential benefit in organ transplantation. Yonsei Med. J. 45 (2004) 991-997
58. Graeler M., et al. Cutting edge: suppression of T cell chemotaxis by sphingosine 1-phosphate. J. Immunol. 169 (2002) 4084-4087
59. Sawicka E., et al. Inhibition of Th1- and Th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720. J. Immunol. 171 (2003) 6206-6214
60. Sanchez T., et al. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J. Biol. Chem. 278 (2003) 47281-47290
61. Zager R.A., et al. Altered ceramide and sphingosine expression during the induction phase of ischemic acute renal failure. Kidney Int. 52 (1997) 60-70
62. Awad A.S., et al. Selective Sphingosine 1-Phosphate 1 (S1P1) Receptor Activation Reduces Ischemia-Reperfusion Injury in Mouse Kidney. Am. J. Physiol. Renal Physiol. (2006)
63. Foss Jr. F.W., et al. Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg. Med. Chem. 15 (2007) 663-677
64. Lai L.W., et al. A sphingosine-1-phosphate type 1 receptor agonist inhibits the early T-cell transient following renal ischemia-reperfusion injury. Kidney Int. 71 (2007) 1223-1231
65. Lien Y.H., et al. S1P(1)-selective agonist, SEW2871, ameliorates ischemic acute renal failure. Kidney Int. 69 (2006) 1601-1608